Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of XC130-A10H in Healthy Adults
NCT04043338Phase 1Unknown
- Sponsor
- Xoc Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing XC130-A10H with Placebo (2 arms). Primary endpoints: Incidence and severity of Adverse Events at 14 days and Changes from baseline in systolic and diastolic blood pressure at 48 hours. Status: unknown.
02
Drugs
XC130-A10H
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04043338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04043338.